Skip to content

Treating Post-Lyme Disease Syndrome With Acetogenins

Using ReaLife+ to Treat Post-Lyme Disease Syndrome

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04078841
Enrollment
30
Registered
2019-09-06
Start date
2019-07-01
Completion date
2020-01-30
Last updated
2020-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Lyme Disease Syndrome (PLDS)

Brief summary

To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS).

Detailed description

To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS). After failure of antibiotic therapy to relive persistent symptoms of Lyme Disease, the use of Acetogenins to elevate Post-Lyme Disease Syndrome.

Interventions

DIETARY_SUPPLEMENTReaLife+ (RLP)

RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.

OTHERInert Brown powder

Brown powder Inert brown powder to look similar to RLP

Sponsors

Optimal Health Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. A positive Western Blot for Lyme Disease that has been treated with antibiotics but the symptoms persist post treatment. 2. Must be able to swallow and mixed powder drink. \-

Exclusion criteria

1. Non Positive Western Blot test. 2. Positive Western Blot test where the indivual has not been treated with antibiotics. \-

Design outcomes

Primary

MeasureTime frameDescription
Blood test3 monthsWestern Blot showing negative
PROMIS Fatigue Scale3 monthsSelf reported fatigue level changes as measured by the Patient-Reported Outcomes Measurement Information System, Fatigue Scale.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026